Efficacy and safety of Empagliflozin in younger, overweight/obese patients with Type 2 diabetes with HbA1c ≥8%

Aim: To assess the efficacy and safety of empagliflozin in younger, overweight/obese patients with type 2 diabetes (T2DM) with HbA1c ≥8%. Methods: Using pooled data from 4 randomized Phase III trials in patients with T2DM, we conducted a post-hoc analysis of patients aged < 65 years with BMI ≥25 to < 35 kg/m2 and HbA1c ≥8% at baseline, who received empagliflozin 10 mg (n = 193), empagliflozin 25 mg (n = 179) or PBO (n = 188) for 24 weeks. Results: Baseline mean (SD) age was 52.1 (7.9) years, BMI was 29.0 (2.7)kg/m2 and HbA1c was 8.72 (0.64)%. Compared with placebo, empagliflozin 10 mg and 25 mg significantly red…